Precigen, Inc
Precigen, Inc. is a U.S.-based biopharmaceutical company focused on precision medicines and platform-enabled product development for difficult-to-treat diseases. Its business combines proprietary technology platforms, clinical-stage therapeutic programs, and the Exemplar subsidiary, which develops and sells genetically engineered miniature swine models.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical and commercial-stage precision medicine programs, including Papzimeos.
Genetically engineered miniature swine models sold through Exemplar.
Revenue from strategic agreements, cancellations, or modifications of prior deals.
Tuotteet
Raportoitu · osuus liikevaihdosta- Service Exemplar89,2 %
- Product Exemplar10,8 %
Lähde: 10-K FY2024, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Precigen sells to research, translational, and commercial customers that need specialized animal models or access to its biotechnology platforms. Its therapeutic business is aimed at patients through healthcare providers and, ultimately, payers and treatment centers once products are commercialized. Collaboration revenue, when present, comes from pharmaceutical or biotechnology partners that license or access platform assets.
Buy Exemplar miniature swine models for preclinical research and translational studies.
Enter licensing or strategic agreements around proprietary platforms and programs.
Would use Papzimeos in the commercial setting for recurrent respiratory papillomatosis.
The end beneficiaries of the company’s therapeutic programs, especially rare diseases.
Strategia
Precigen is prioritizing the transition from a platform-development company toward a commercial-stage biopharmaceutical business. The core strategic focus is to launch Papzimeos, advance proprietary programs, and use platform assets to create additional product and collaboration opportunities. Exemplar remains a current revenue source while the company builds a broader therapeutic portfolio.
A successful launch would shift the company toward recurring product sales and validate the platform.
Pipeline progression is needed to diversify revenue beyond Exemplar and collaborations.
Collaborations can provide non-dilutive capital and external validation of the technology base.
Maantiede
2024Precigen is headquartered in the United States and its reported business activity is centered there. The company’s research, development, and commercial execution are tied to U.S. regulatory and market access pathways, while Exemplar and platform collaborations may extend to external partners outside the U.S. No country-level revenue breakdown was disclosed in the provided excerpts.
Riskit
Precigen faces the typical risks of a development-stage biopharmaceutical company: regulatory uncertainty, clinical and manufacturing execution risk, and dependence on future product launches. The company also has material financing and leverage risk, plus impairment risk tied to goodwill, intangible assets, and strategic transactions involving its operating units.
- Going-concern and financing riskVaikutus: KriittinenTodennäköisyys: Matala
The company may need additional capital if commercialization and other revenues do not scale as planned.
Kohdistuu: Corporate liquidity and operations
- Debt and covenant riskVaikutus: KorkeaTodennäköisyys: Matala
Senior secured term debt adds mandatory interest, principal amortization, and restrictive covenants.
Kohdistuu: Balance sheet and operating flexibility
- Regulatory and commercialization risk for PapzimeosVaikutus: Korkea
Revenue depends on successful approval, launch, and market adoption of a new gene therapy.
Kohdistuu: Therapeutic product revenue
- Development-stage biotech execution riskVaikutus: Korkea
Clinical, manufacturing, and scale-up activities can be delayed or cost more than expected.
Kohdistuu: Pipeline programs and platform assets
- Impairment risk for goodwill and intangible assetsVaikutus: Keskitaso
Strategic changes or weaker fair value assumptions could trigger non-cash impairment charges.
Kohdistuu: Operating units and reporting units
Kirjanpito
Harkinnanvaraiset erätDifferent revenue streams use different timing rules, affecting quarterly comparability.
Vaikutus: Product sales, services, and collaboration revenue
Management notes that strategic transactions or valuation changes could trigger impairment charges.
Vaikutus: Non-cash operating expense and equity
License agreements may create contingent future payments tied to development or sales outcomes.
Vaikutus: Future cash obligations and expense recognition
Operating lease commitments affect reported liabilities and fixed cash outflows.
Vaikutus: Balance sheet and liquidity analysis
Unincurred third-party research commitments indicate future spending requirements.
Vaikutus: Cash burn and expense visibility
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Precision BioSciences, Inc
DTIL · Biological Products, (No Diagnostic Substances)
Precision BioSciences is a U.S.-based clinical-stage gene editing company built around its proprietary ARCUS genome editing platform.
Precipio, Inc.
PRPO · Laboratory Analytical Instruments
Pyxis Oncology, Inc.
PYXS · Pharmaceutical Preparations
Praxis Precision Medicines, Inc.
PRAX · Pharmaceutical Preparations
Provectus Biopharmaceuticals, Inc.
PVCT · Pharmaceutical Preparations
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Päivitetty: 24.9.2026